Abstract:Abstract Among all cancer types, pancreatic ductal adenocarcinoma (PDAC) has one of the worst outcomes. In recent studies, metabolic and microenvironmental reprogramming in PDAC has been shown to facilitate tumor progression by promoting immune escape mechanisms, however these mechanisms are still poorly understood. Recently, our lab established that autotaxin (ATX) - lysophosphatidic acid (LPA) signaling in PDAC enhances tumorigenicity, but the immunomodulatory function of this signal pathway remains largely unexplored. We now show that ablation of the LPA-producing enzyme autotaxin (ATX) in PDAC cells can reduce tumor burden in mice and reprogram the tumor immune microenvironment by increasing tumor eosinophil infiltration. The functional role of eosinophils in the context of PDAC is a poorly understood area. The presence of eosinophils in pancreatic cancer has been reported in a few case reports: for example, prior studies identified neutrophils and eosinophils together as a group, expressing high levels of CD66b. We confirmed the presence of eosinophils in PDAC in mice as well as patients, and we found that rare patient samples with the highest intratumoral eosinophil abundance had the longest survival rates. Genetic or pharmacologic ATX inhibition increased intratumoral eosinophils, which promote tumor cell apoptosis locally and suppress tumor progression. When eosinophils were present, primary tumor growth was modestly reduced, but metastatic spread was greatly reduced. Mechanistically, ATX suppresses eosinophil accumulation via an autocrine feedback loop wherein ATX-LPA signaling negatively regulates activity of AP-1 transcription factor c-Jun, in turn suppressing expression of potent eosinophil chemoattractant CCL11 (Eotaxin-1). This is the first study that highlights the anti-tumor potential of eosinophils in pancreatic cancer. Citation Format: Sohinee Bhattacharyya, Chet Oon, Holly Sandborg, Terry Morgan, Mara H. Sherman. Autotaxin-lysolipid signaling suppresses a CCL11- eosinophil axis to promote pancreatic cancer progression [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr A025.

Hepatocyte autotaxin expression promotes liver fibrosis and cancer

Roles of Autotaxin/Autotaxin-Lysophosphatidic Acid Axis in the Initiation and Progression of Liver Cancer

Autotaxin in Pathophysiology and Pulmonary Fibrosis

The Expression Regulation and Biological Function of Autotaxin

Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis

Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis

High expression of autotaxin is associated with poor recurrence‐free survival in cholangiocarcinoma

Tumor immune escape by autotaxin: keeping eosinophils at bay

Inhibition of autotaxin by bile salts and bile salt-like molecules increases its expression by feedback regulation

Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer

Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs

Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis

Autotaxin: An Early Warning Biomarker For Acute-On-Chronic Liver Failure

Overexpression of Autotaxin is Associated with Human Renal Cell Carcinoma and Bladder Carcinoma and Their Progression

Deleting autotaxin in LysM+ myeloid cells impairs innate tumor immunity in models of metastatic melanoma

The Autotaxin–LPA Axis Emerges as a Novel Regulator of Lymphocyte Homing and Inflammation

Abstract A025: Autotaxin-lysolipid signaling suppresses a CCL11- eosinophil axis to promote pancreatic cancer progression

Autotaxin Production of Lysophosphatidic Acid Mediates Allergic Asthmatic Inflammation

A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis

Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases

Five-lipoxygenase-activating Protein-Mediated CYLD Attenuation is a Candidate Driver in Hepatic Malignant Lesion